Company Description
PureTech Health plc, engages in the development and commercialization of biotechnology and pharmaceutical solutions in the United States.
The company is developing LYT-100, which is under Phase 2 stage, to treat idiopathic pulmonary fibrosis (IPF); and LYT-200, a IgG4 monoclonal antibody, currently under Phase 1/2 stage, targeting galectin-9 for treating solid tumors and hematological malignancies.
It also develops SPT-300, an oral drug of allopregnanolone for the treatment of anxious depression; SPT-320, a novel prodrug of agomelatine for the treatment of generalized anxiety disorder; and SPT-348, a prodrug of a non-hallucinogenic neuroplastogen for the treatment of mood and other neuropsychiatric disorders.
In addition, the company is developing hydrogels to enable the oral administration of peptide therapeutics in preclinical development.
The company was incorporated in 2015 and is headquartered in Boston, Massachusetts.
| Country | United States |
| Founded | 2015 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 90 |
| CEO | Bharatt Chowrira |
Contact Details
Address: 6 Tide Street, Suite 400 Boston, Massachusetts 02210 United States | |
| Phone | 617 482 2333 |
| Website | puretechhealth.com |
Stock Details
| Ticker Symbol | PRTC |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001782999 |
| CUSIP Number | 746237106 |
| ISIN Number | US7462371060 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Bharatt M. Chowrira J.D., Ph.D. | Chief Executive Officer and Executive Director |
| Daphne Zohar | Founder, Senior Advisor and Board Observer |
| Dr. Robert S. Langer Jr., Ph.D., ScD | Co-Founder and Non-Executive Director |
| Dr. Eric Elenko Ph.D. | Co-Founder and President |
| Dr. David R. Elmaleh Ph.D. | Co-Founder and Senior Advisor |
| Michael Inbar CPA, M.B.A. | Senior Vice President of Finance |
| Eric Green M.B.A. | Chief Operating Officer |
| Allison Mead Talbot | Head of Communications and Investor Relations |
| Charles Sherwood III, J.D., Ph.D. | General Counsel and Company Secretary |
| Spencer Ball | Senior Vice President of Human Resources |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Oct 21, 2024 | 6-K | Report of foreign issuer |
| Sep 27, 2024 | 6-K | Report of foreign issuer |
| Aug 28, 2024 | 6-K | Report of foreign issuer |
| Aug 28, 2024 | 6-K | Report of foreign issuer |
| Aug 22, 2024 | 6-K | Report of foreign issuer |
| Jul 8, 2024 | 4 | Statement of changes in beneficial ownership of securities |
| Jun 24, 2024 | 6-K | Report of foreign issuer |
| Jun 24, 2024 | SC TO-I/A | Filing |
| Jun 20, 2024 | 6-K | Report of foreign issuer |
| Jun 13, 2024 | 6-K | Report of foreign issuer |